web analytics
4.6 C
Munich
Sunday, April 18, 2021

The Exciting Rise of Cannagistics Inc (OTCMKTS: CNGT)

Cannagistics Inc (OTCMKTS: CNGT) is making a big move up the charts in recent weeks off its double zero lows to recent highs well into penny land. The stock has quickly attracted legions of shareholders and has established itself as a volume leader in small caps. Reverse Merger plays are some of the biggest runners in small caps rivaling only biotechs in their ability to make historic shot term gains.

CNGT has been heating up since the Company got new CEO Jam Rob Gietl on board who was most recently, Until March 2020 the Interim CEO of Availa Bio, Inc., a company engaged in the development of numerous patented and patent pending products in the health and wellness space. According to an 8k filed by PBIO; “Pressure BioSciences, Inc. entered into a binding letter of intent to merge with Cannaworx Holdings, Inc. Pursuant to the Second Amendment, the parties extended the September 30, 2020 deadline to October 31, 2020.

Cannagistics Inc (OTCMKTS: CNGT) is a complete end to end supply chain management company, with advanced technology and operating service subsidiaries. Our Proprietary technology platforms will provide a turnkey onramp for access and services worldwide [for growers, processors, and buyers] to tap into the ever-expanding worldwide cannabis marketplace.Global 3PL. operates bonded warehousing in Mississauga (the first Canadian company to obtain a license for cannabis), which shall serve both the cannabis and general commodities industries with Just In Time Inventory, ground, air, and ocean freight transport, international freight forwarding, and Custom House Brokerage. Cannagistics also entered into a letter of intent to acquire anISO 9000 research and testing lab looking to expand its operations to  Florida, Las Vegas, Oregon, California, Canada, and Bogotá, Colombia. We will also pursue operations in the E.U., based in Poland.

The Company is led by CEO by new CEO Rob Gietl was most recently, Until March 2020 the Interim CEO of Availa Bio, Inc., a company engaged in the development of numerous patented and patent pending products in the health and wellness space. From April 2017 to February 2019, Mr. Gietl was CEO of MYM Nutraceuticals Inc., an emerging bio-pharmaceutical company and distributor of medical cannabis products. He previously served from September 2015 to March 2017as the Director of Business Development at NRI Global Inc. where he led industrial acquisitions, environmental remediation and global sales of reusable assets and commodities

To Find out the inside Scoop on CNGT Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BLFERecently PBIO announced plans to change its name to Avalia Bio following its acquisitions of and merger with Cannaworx Inc and SkinScience Labs Inc. PBI CEO Richard Schumacher stated:  “PBI’s UST platform offers the potential to deliver an extraordinary breakthrough in creating unique, high quality nanoemulsions of oil in water. A vast range of personal care and consumption products, including nutraceuticals, cosmetics, pharmaceuticals, food & beverages, all face the perplexing challenge of getting active oil-based nutrients or therapeutic ingredients to become easily absorbable and effective in the water-based biology of our bodies.”

Cannaworx and its principals have 12 products, including several that utilize the company’s patented and patent pending hemp-derived phytocannabinoid formations for pain relief.  The parties believe UST processing will increase the efficacy of Cannaworx products, reduce manufacturing costs, increase profits and distinguish its product lines. Over the next few months, the plan is to roll out two patented oral phytocannabinoid formulations for pain relief allowed under an FDA OTC monograph. The combined Avalia Bio has an IP estate of 31 issued and a dozen or more pending patents, as well as an existing global base of hundreds of corporate and thousands of retail customers.

For more on CNGT subscribe Right Now!

CNGT is making a big move up the charts in recent weeks off its double zero lows to recent highs well into penny land. The stock has quickly attracted legions of shareholders and has established itself as a volume leader in small caps. CNGT has been heating up since the Company got new CEO Rob Gietl on board who was most recently, Until March 2020 the Interim CEO of Availa Bio, Inc., a company engaged in the development of numerous patented and patent pending products in the health and wellness space. According to an 8k filed by PBIO; “Pressure BioSciences, Inc. entered into a binding letter of intent to merge with Cannaworx Holdings, Inc. recently the parties extended the September 30, 2020 deadline to October 31, 2020. The combined Avalia Bio has an IP estate of 31 issued and a dozen or more pending patents, as well as an existing global base of hundreds of corporate and thousands of retail customers. CNGT has 158 million OS with AS set at 500 million. The primary shareholders are Rob Gietl and James Zimler. We will be updating on CNGT when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CNGT.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in CNGT either long or short and we have not been compensated for this article.

More articles

2 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.